Fundamental Analysis of NEUROGENE INC(NASDAQ:NGNE) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to NGNE. NGNE was compared to 565 industry peers in the Biotechnology industry. While NGNE seems to be doing ok healthwise, there are quite some concerns on its profitability. NGNE has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

NGNE had negative earnings in the past year.

In the past year NGNE has reported a negative cash flow from operations.

In the past 5 years NGNE always reported negative net income.

NGNE had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -43.34%, NGNE perfoms like the industry average, outperforming 53.02% of the companies in the same industry.

NGNE has a better Return On Equity (-51.76%) than 65.66% of its industry peers.

		Industry Rank	Sector Rank
ROA	-43.34%
ROE	-51.76%
ROIC	N/A

ROA(3y)-34.38%

ROA(5y)-33.24%

ROE(3y)-41.01%

ROE(5y)-37.89%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NGNE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, NGNE has more shares outstanding

Compared to 5 years ago, NGNE has more shares outstanding

Compared to 1 year ago, NGNE has an improved debt to assets ratio.

2.2 Solvency

NGNE has an Altman-Z score of 4.56. This indicates that NGNE is financially healthy and has little risk of bankruptcy at the moment.

With a decent Altman-Z score value of 4.56, NGNE is doing good in the industry, outperforming 79.18% of the companies in the same industry.

A Debt/Equity ratio of 0.00 indicates that NGNE is not too dependend on debt financing.

NGNE's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. NGNE outperforms 50.00% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	4.56

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

NGNE has a Current Ratio of 9.09. This indicates that NGNE is financially healthy and has no problem in meeting its short term obligations.

NGNE's Current ratio of 9.09 is fine compared to the rest of the industry. NGNE outperforms 77.94% of its industry peers.

NGNE has a Quick Ratio of 9.09. This indicates that NGNE is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of NGNE (9.09) is better than 77.94% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	9.09
Quick Ratio	9.09

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.51% over the past year.

EPS 1Y (TTM)67.51%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-190.24%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NGNE will show a small growth in Earnings Per Share. The EPS will grow by 0.02% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y22.2%

EPS Next 2Y10.6%

EPS Next 3Y0.02%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NGNE. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NGNE. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y10.6%

EPS Next 3Y0.02%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

NGNE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NEUROGENE INC

NASDAQ:NGNE (12/20/2024, 8:26:56 PM)

After market: 22.64 0 (0%)

22.64

+0.57 (+2.56%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-18 2024-11-18/amc

Earnings (Next)N/A N/A

Inst Owners102.46%

Inst Owner Change4.53%

Ins Owners9.79%

Ins Owner Change5.12%

Market Cap336.20M

Analysts87.69

Price Target53.86 (137.9%)

Short Float %8.77%

Short Ratio2.78

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)1.36%

Min EPS beat(2)-1.77%

Max EPS beat(2)4.5%

EPS beat(4)2

Avg EPS beat(4)-2.46%

Min EPS beat(4)-26.17%

Max EPS beat(4)13.62%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-5.04%

PT rev (3m)2.72%

EPS NQ rev (1m)2.73%

EPS NQ rev (3m)-5.28%

EPS NY rev (1m)1.59%

EPS NY rev (3m)1.97%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)102.75%

Revenue NY rev (3m)102.75%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	363.46
P/FCF	N/A
P/OCF	N/A
P/B	2.45
P/tB	2.45
EV/EBITDA	N/A

EPS(TTM)-4.79

EYN/A

EPS(NY)-4.42

Fwd EYN/A

FCF(TTM)-5.63

FCFYN/A

OCF(TTM)-5.6

OCFYN/A

SpS0.06

BVpS9.25

TBVpS9.25

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-43.34%
ROE	-51.76%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-34.38%

ROA(5y)-33.24%

ROE(3y)-41.01%

ROE(5y)-37.89%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score2

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	8.92%
Cap/Sales	50.05%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	9.09
Quick Ratio	9.09
Altman-Z	4.56

F-Score2

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)109.95%

Cap/Depr(5y)173.94%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)67.51%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-190.24%

EPS Next Y22.2%

EPS Next 2Y10.6%

EPS Next 3Y0.02%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-168.15%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-73.39%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-77.58%

OCF growth 3YN/A

OCF growth 5YN/A

NEUROGENE INC (NGNE)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens